Christoph Schraeder

Title: Christoph Schraeder: Innovator in Immunotherapy

Introduction

Christoph Schraeder is a prominent inventor based in Tuebingen, Germany. He has made significant contributions to the field of immunotherapy, particularly in the development of peptides for cancer treatment. With a total of five patents to his name, Schraeder is recognized for his innovative approaches to combating various types of cancers.

Latest Patents

Schraeder's latest patents include groundbreaking work on amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers. This invention relates to a peptide comprising an amino acid sequence selected from a specific group, which maintains the capacity to bind to MHC molecules and induce T cells that cross-react with the variant peptide. Another notable patent involves amidated peptides and their deamidated counterparts displayed by non-HLA-A*02, also aimed at immunotherapy for different types of cancers. This invention similarly focuses on a peptide with a specific amino acid sequence that retains the ability to bind to MHC molecules and induce T cell responses.

Career Highlights

Christoph Schraeder is currently associated with Immatics Biotechnologies GmbH, where he continues to advance his research in immunotherapy. His work has positioned him as a key figure in the development of innovative cancer treatments.

Collaborations

Schraeder collaborates with notable colleagues, including Jens Hukelmann and Heiko Schuster, contributing to a dynamic research environment that fosters innovation in the field of biotechnology.

Conclusion

Christoph Schraeder's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the fight against cancer. His work continues to inspire advancements in medical science and offers hope for improved treatment options.